Section Arrow
GERN.NASDAQ
- Geron Corp
Quotes are at least 15-min delayed:2024/05/02 09:30 EDT
Last
 4.11
+0.03 (+0.74%)
Day High 
4.14 
Prev. Close
4.08 
1-M High
4.3 
Volume 
86.36K 
Bid
4.09
Ask
4.1
Day Low
4.11 
Open
4.14 
1-M Low
3.05 
Market Cap 
2.40B 
Currency USD 
P/E -- 
%Yield
10-SMA 3.77 
20-SMA 3.63 
50-SMA 2.99 
52-W High 4.3 
52-W Low 1.64 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.32/-0.43
Enterprise Value
2.44B
Balance Sheet
Book Value Per Share
0.42
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
237.00K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ALLRAllarity Therapeutics3.02+1.65+120.44%-- 
CNTXContext Therapeutics1.75+0.39+28.68%-- 
APVOAptevo Therapeutics1.13+0.17+17.71%-- 
JAGXJaguar Health0.2262+0.0012+0.53%-- 
CTMXCytomX Therapeutics4.33-0.8-15.59%-- 
Quotes are at least 15-min delayed:2024/05/02 09:30 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.